for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,604.60GBp

Change

-12.40(-0.77%)

Volume

4,178,909

Today's Range

1,601.00

 - 

1,628.00

52 Week Range

1,328.19

 - 

1,857.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,617.00
Open
1,609.20
Volume
4,178,909
3M AVG Volume
161.21
Today's High
1,628.00
Today's Low
1,601.00
52 Week High
1,857.00
52 Week Low
1,328.19
Shares Out (MIL)
5,017.27
Market Cap (MIL)
81,129.28
Forward P/E
13.73
Dividend (Yield %)
4.95

Next Event

GlaxoSmithKline PLC to Discuss HIV Prevention Treatment Network 083 Study Call

Latest Developments

More

GSK Says Long-Acting Injectable Cabotegravir 66% More Effective Than Truvada

GSK Says Long-Acting Injectable Cabotegravir 65% More Effective Than Truvada

GSK And Medicago To Collaborate On Developing Novel Adjuvanted Covid-19 Candidate Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Biotechnology & Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://india-pharma.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.50 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

30.2K

2018

30.8K

2019

33.8K

2020(E)

35.4K
EPS (GBp)

2017

111.800

2018

119.400

2019

123.900

2020(E)

117.793
Price To Earnings (TTM)
15.08
Price To Sales (TTM)
2.31
Price To Book (MRQ)
6.12
Price To Cash Flow (TTM)
11.10
Total Debt To Equity (MRQ)
244.43
LT Debt To Equity (MRQ)
188.95
Return on Investment (TTM)
13.16
Return on Equity (TTM)
8.13

Latest News

Latest News

BRIEF-GSK And Medicago To Collaborate On Developing Novel Adjuvanted Covid-19 Candidate Vaccine

* GSK AND MEDICAGO ANNOUNCE COLLABORATION TO DEVELOP A NOVEL ADJUVANTED COVID-19 CANDIDATE VACCINE

Britain nears 500 million stg supply deal for Sanofi/GSK COVID-19 vaccine - Sunday Times

Britain is close to agreeing a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COVID-19 vaccine, the Sunday Times reported.

U.S. FDA approves GSK's HIV drug for patients with limited options

The U.S. Food and Drug Administration on Thursday approved GlaxoSmithKline Plc's HIV drug, Rukobia, to treat adult patients who have run out of treatment options.

GSK says it is within weeks of resubmitting HIV injection Cabenuva

GlaxoSmithKline's HIV business ViiV is within weeks of resubmitting its request for approval of its long-acting injection Cabenuva to U.S. drug regulators, ViiV's head of research said on Thursday.

BRIEF-GSK’S Daprodustat Gains First Regulatory Approval

* GLAXOSMITHKLINE PLC - GSK’S DAPRODUSTAT GAINS FIRST REGULATORY APPROVAL

RPT-GSK in quest to be best, not first, in race for COVID-19 vaccine

There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline.

GSK in quest to be best, not first, in race for COVID-19 vaccine

There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline <GSK.L>.

BRIEF-GSK's Covid-19 Vaccine Collaboration With Clover Biopharmaceuticals Begins Trials

* GSK COVID-19 VACCINE DEVELOPMENT COLLABORATION WITH CLOVER BIOPHARMACEUTICALS BEGINS CLINICAL TRIALS

BRIEF-GSK Prices $280.3 Mln Notes Due 2023 Exchangeable Into Theravance Biopharma Shares

* GSK - GSK PRICES $280.3 MILLION SENIOR NOTES DUE 2023 EXCHANGEABLE INTO THERAVANCE BIOPHARMA ORDINARY SHARES Source text for Eikon: Further company coverage:

BRIEF-GSK Proposes Unregistered Offering Of Senior Notes Exchangeable Into Theravance Biopharma Shares

* ANNOUNCES PROPOSED UNREGISTERED OFFERING OF SENIOR NOTES EXCHANGEABLE INTO THERAVANCE BIOPHARMA ORDINARY SHARES

BRIEF-GSK And Ideaya Announce Broad Partnership In Synthetic Lethality

* GSK - IDEAYA AND GSK ANNOUNCE A BROAD PARTNERSHIP IN SYNTHETIC LETHALITY, AN EMERGING FIELD IN PRECISION MEDICINE ONCOLOGY

BRIEF-Glaxo Smithkline Consumer Nigeria Qtrly Group Pretax Profit 166.9 Mln Naira Vs 150.6 Mln Naira

* GLAXO SMITHKLINE CONSUMER NIGERIA PLC - QTRLY GROUP PROFIT BEFORE TAX 166.9 MILLION NAIRA VERSUS 150.6 MILLION NAIRA

GSK aims for one billion doses of booster as COVID-19 vaccine race heats up

GSK <GSK.L>, the world's largest vaccine maker, laid out plans on Thursday to produce 1 billion doses of vaccine efficacy boosters for COVID-19 shots next year, as the race to develop a successful solution to the coronavirus crisis heats up.

GSK to produce 1 bln doses of adjuvant vaccine booster in 2021

British drugmaker GlaxoSmithKline Plc will expand production of vaccine efficacy boosters, or adjuvants, to produce 1 billion doses in 2021 for use in shots for COVID-19, the company said on Thursday.

BRIEF-GSK Announces Intention To Produce 1 Bln Doses Of Pandemic Vaccine Adjuvant In 2021

* GSK - ANNOUNCES INTENTION TO PRODUCE 1 BILLION DOSES OF PANDEMIC VACCINE ADJUVANT IN 2021 TO SUPPORT MULTIPLE COVID-19 VACCINE COLLABORATIONS

BRIEF-GSK Says FDA Grants Priority Review Of Nucala For Patients With HES

* GSK - FDA GRANTS PRIORITY REVIEW OF NUCALA FOR PATIENTS WITH HYPEREOSINOPHILIC SYNDROME (HES)

South Korea's Samsung Biologics signs $231 million supply deal with GSK

South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than $231 million with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years.

BRIEF-GSK Partners With Samsung Biologics To Secure Additional Manufacturing Capacity For Innovative Biopharmaceutical Portfolio

* GSK PARTNERS WITH SAMSUNG BIOLOGICS TO SECURE ADDITIONAL MANUFACTURING CAPACITY FOR INNOVATIVE BIOPHARMACEUTICAL PORTFOLIO

GSK ties up with gene editing start-up Mammoth for COVID-19 test

GlaxoSmithKline's consumer health unit has tied up with Mammoth Biosciences to develop a test that uses a technology commonly used in gene editing to detect novel coronavirus infections, the California-based startup said on Wednesday.

GSK ties up with gene editing start-up Mammoth for COVID-19 test

GlaxoSmithKline's consumer health unit has tied up with Mammoth Biosciences to develop a test that uses a technology commonly used in gene editing to detect novel coronavirus infections, the California-based startup said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up